The patent bio keeps referring to dates back to 2003, prior to Ramon coming to PPHM.
Ex, you are absolutely correct, that the patent filed, has a priority date and filing date "before" Ramon decides to work with Peregrine Pharmaceuticals on a full time basis, though one must dig just a tad bit deeper.... to realize what happened.
Actually, this is a nice beginners version of puzzle solving and at the same time, it really makes one ask the question why one would try to diffuse the following facts and here is my quick summary:
1) Ramon Valencia was studying to become a Patent Agent as he begain working with Burstein Technologies as a Scientist in Dec of 1999.
2) Ramon was handed responsibility to work with Peregrine Pharmaceuticals during employment at Burstein and Peregrine liked what they say, obviously... because what does a company do after completion of all the paperwork, interviews..etc to examine prior art..etc by Ramon ... and after priority date submitted on Sept 3, 2003 and filing date finally submitted on Sept 2, 2004
3) So what does a company do...I'll tell what a company does... they hire them and bring them on board for obvious reasons. So yes, the final date to key in on is the hiring date at Peregrine, which shows Jan of 2004 (just a few months after the filing date of Sept 2, 2004)
Now think about it, there is NO WAY that the Ramon Valencia patent does not pertain to Peregrine, but Ex, you are still correct: in that the patent I'm talking about goes back to BEFORE Peregrine hired Ramon.
So digging deeper... Ramon passes Patent Agent exam in 2002 and officially makes use of it in 2003, just as Ramon takes "Effective Negotiations" in 2015 and may also make very good use of it immediately re: Dr. Jedd Wolchok..etc and maybe, those are all just little stepping stones to a much BIGGER deal that one would also try and diffuse.
Publication number US9133024 B2 Publication type Grant Application number US 10/934,665 Publication date Sep 15, 2015 Filing date Sep 2, 2004 Priority date Sep 3, 2003
A personal diagnostic patch device for biological analysis includes a sample acquisition layer for obtaining a fluid sample, a fluidic processing layer including a fluidic circuit for directing fluid flow, an assay results detection layer having a detector for detecting diagnostic results derived from fluid sample analysis, and a processor and transmitter for sending diagnostic results to a remote location. The layers are situated in register with each other and operatively attached with constituent elements in alignment to form the fluidic circuit for sample processing, detection, and analysis. Related systems include a remotely located user computer for receiving a signal from the patch device when the device is provided with the transmitter. The user computer may be connected to a network including any one or more of several different medical providers. Methods include use of the patch device for specific applications, related processes, and steps for manufacturing and assembling.
Patent Agent/Scientist Burstein Technologies December 1999 – December 2003 (4 years 1 month)Irvine, CA
.. ..
Registered U.S. Patent Agent United States Patent and Trademark Office Starting February 2002
.. ..
January 2004 – May 2010 (6 years 5 months)
• Drafted and negotiate term sheets for key financial and legal licensing terms. • Developed negotiation strategies and negotiate key licensing provisions in licensing agreements. • Drafted, reviewed and negotiated terms for legal agreements including: licensing, collaboration, materials transfer, sponsored research, confidentiality and contract manufacturing agreements. • Managed contractual obligations and enforce various company agreements (Alliance Management). • Developed docketing system for tracking contracts and various agreements. • Assisted outside counsel in preparation and prosecution of patent applications. • Managed Tumor Necrosis Therapy, Vascularpermeability Enhancing Agent & Permeability Enhancing Peptide patent portfolios. • Worked with scientists and outside counsel to ensure company inventions are appropriately protected. • Appled IP protection strategies at all levels. • Assisted in analysis of patentability. • Performed freedom to operate analysis. • Worked together with management to secure and develop its IP position. • Directed company litigation proceedings. • Assisted with trademark filings.
.. ..
Senior Manager, Business Development & Licensing Peregrine Pharmaceuticals June 2010 – Present (6 years 6 months)Tustin, CA
• Accomplishments: • Instrumental in establishing a relationship with Dr. Jedd Wolchock and colleagues at Memorial Sloan Kettering that led to a research and multiple clinical collaborations in Immunotherapy to validate Peregrine PS targeting immune modulator and identify and develop new targets for immunotherapy. • Worked closely with VP of BD on the Dios Therapeutics deal - $50 Million; resulted in 35% increase in PPHM Market Cap • Negotiated major terms and drafted, from scratch, two license agreements with Affitech for Anti-VEGF antibodies. • Successfully negotiated various in and out licensing deals listed below.
Duties and Responsibilities: • Drive deal process from first contact with potential partners and collaborators to execution of agreements • Identify new opportunities to support Peregrine’s businesses • Interface with all functional groups to investigate and evaluate opportunities in sufficient depth to define the values, risks, fit, technical feasibility, benefits and fundamental structure of the deals. • Coordinate evaluation of new opportunities across multiple functional areas including Research, Clinical, Regulatory, Commercial, Manufacturing, Finance, Legal, Intellectual Property and other groups • Independently and in collaboration with internal groups, work to provide detailed economic analyses of new opportunities (e.g., market research, business intelligence, competitive analysis, development plan, commercial forecast, NPV analyses) to inform business decisions • Present business rationale, analyses and proposals to senior executives and interface with senior management to reach agreement • Develop deal concepts and negotiate term sheets and definitive agreements • Participate in deal execution including due diligence, facilitating interactions across all functional areas. • Work closely with finance and legal groups to structure and execute complicated transactions. Patent Agent & Manager, Legal Dept. Peregrine Pharmaceuticals
... and for an added Friday night bonus: Ramon Valencia recommends Taylor Schreiber for Immunology, Molecular Biology, Cancer..etc...etc...and etc... all just pieces to the much bigger puzzle but have touched on this before.. with Rahul(the PS Targeting pro analyst that jumps on BOD of Pelican...) Taylor Schreiber, Josiah Hornblower...
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
